Effective of .ALPHA.1 Blocker, Doxazosin to Small Dense LDL Cholesterol and Urinary Oxidative Stress in Type 2 Diabetes Patients with Hypertension
|
Accession number;06A0891768
|
| Title;Effective of .ALPHA.1 Blocker, Doxazosin to Small Dense LDL Cholesterol and Urinary Oxidative Stress in Type 2 Diabetes Patients with Hypertension |
| Author;
OKADA KENTA
(Showa Univ., School of Medicine, JPN)
HIRANO TSUTOMU
(Showa Univ., School of Medicine, JPN)
MORI YUSAKU
(Showa Univ., School of Medicine, JPN)
HAYASHI TOSHIYUKI
(Showa Univ., School of Medicine, JPN)
YAMAO SAYAKA
(Showa Univ., School of Medicine, JPN)
SHIRAISHI YUJI
(Showa Univ., School of Medicine, JPN)
ADACHI MITSURU
(Showa Univ., School of Medicine, JPN)
|
Journal Title;Ther Res
|
Journal Code:Y0681A
|
ISSN:0289-8020
|
|
VOL.27;NO.10;PAGE.1999-2003(2006)
|
| Figure&Table&Reference;TBL.4, REF.18 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Small dense low density lipoprotein (LDL) are potent atherogenic lipoproteins often elevated in the plasma of patients with type 2 diabetes, which leads to the formation of lipid rich plaque. In the past we have reported that Doxazosin could increase the LDL size, which means that it reduced atherogenic lipoproteins. Recently, we establish a simple method for the quantification of small dense LDL cholesterol (-C) using heparin-magnesium precipitation. We determined the effect of Doxazosin in type 2 diabetes with hypertension. Patinets received Doxazosin 2.3.+-.0.75 mg/day for 3 months. Systolic and diastolic BP decreased from 172.+-.17 mmHg to 137.+-.15 mmHg and from 92.+-.11 mmHg to 76.+-.11 mmHg, respectively. Small dense LDL-C levels was sinigificantly reduced within 3 months. These results suggest that Doxazosin may help to prevent CHD by reducing atherogenic lipoproteins, including small dense LDL-C in diabetes with hypertension. (author abst.) |
|
|
|
Related Articles;
|
|
